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TITLE: How accurate and effective are screening tools and subsequent interventions for intimate 
partner violence in non-high-risk settings (IPV)? A rapid review
ABSTRACT: 
To estimate the accuracy and effectiveness of screening tools and subsequent interventions in the 
detection and treatment of intimate partner violence (IPV) in non-high-risk settings (defined here as 
those in which routine IPV screening does not take place in the UK, such as in General Practice).
Rapid review as defined by Grant and Booth â€“ it is used under time or financial constraint to assess 
what is known using systematic review methods.
Medline, PsycINFO, Embase and Cochrane Library databases to May 2019 were searched for 
â€œintimate partner violenceâ€฀ and synonyms plus terms related to screening and interventions. A 
Medline update was performed in August 2020. Data were extracted with the help of a predesigned 
tool and were synthesized to answer the two study aims. Data were mixed quantitative and 
qualitative.
The search yielded 10 relevant papers on screening (6 on accuracy and 4 on effectiveness) and 13 on 
intervention. These showed evidence of the effectiveness of simple screening tools and of 
subsequent interventions. However, the evidence was insufficient to support a change in UK 
guidelines which currently do not recommend their use outside of current high-risk environments.
CUST_RESEARCH_LIMITATIONS/IMPLICATIONS_(LIMIT_100_WORDS) :No data available.
CUST_PRACTICAL_IMPLICATIONS_(LIMIT_100_WORDS) :No data available.
A rapid review design was used in accordance with the requirements of the funder and the 
associated short time frame available. This is less thorough than a systematic review. For example, 
there was no search for grey or unpublished. In addition, quality appraisal of the articles was 
performed but not used formally in a meta-analysis. Finally, as already noted, the rapid review was 
performed under guidelines set out before the most recent update
Identification of an appropriate screening tool is an important issues affecting health and social care 
professionals ability to identify and respond to intimate partner violence. This papers provide 
important insights about the effective screening tools and IPV interventions.
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How accurate and effective are screening tools and subsequent 
interventions for intimate partner violence in non-high-risk settings 
(IPV)? A rapid review
ABSTRACT
Purpose: To estimate the accuracy and effectiveness of screening tools and 
subsequent interventions in the detection and treatment of intimate partner 
violence (IPV) in non-high-risk settings (defined here as those in which 
routine IPV screening does not take place in the UK, such as in General 
Practice).
Design: Rapid review as defined by Grant and Booth – it is used under time 
or financial constraint to assess what is known using systematic review 
methods.
Methods: Medline, PsycINFO, Embase and Cochrane Library databases to 
May 2019 were searched for “intimate partner violence” and synonyms plus 
terms related to screening and interventions. A Medline update was 
performed in August 2020. Data were extracted with the help of a 
predesigned tool and were synthesized to answer the two study aims. Data 
were mixed quantitative and qualitative. 
Results: The search yielded 10 relevant papers on screening (6 on accuracy 
and 4 on effectiveness) and 13 on intervention. These showed evidence of 
the effectiveness of simple screening tools and of subsequent interventions. 
However, the evidence was insufficient to support a change in UK guidelines 
which currently do not recommend their use outside of current high-risk 
environments. 
Conclusion: Clinicians outside of high-risk areas should consider the use of 
some IPV screening tools and interventions but only within research 
protocols in order to gather further evidence.
Key words: intimate partner violence, domestic violence, spouse abuse, 
screening, interventions
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How accurate and effective are screening tools and subsequent 
interventions for intimate partner violence in non-high-risk settings 
(IPV)? A rapid review
1 Introduction
Intimate partner violence (IPV) is a form or subset of domestic violence and 
abuse (DVA). DVA is defined in the UK as, 
“any incident or pattern of incidents of controlling, coercive, threatening 
behaviour, violence or abuse between those aged 16 or over who are, or have 
been, intimate partners or family members regardless of gender or sexuality. 
The abuse can encompass, but is not limited to psychological, physical, 
sexual, financial or emotional.” 1
This definition also encompasses acts of ‘honour’ based violence, female 
genital mutilation (FGM) [cutting] and forced marriage. DVA can manifest in 
several forms, including child abuse, elder abuse and intimate partner 
violence (IPV). All of these except IPV can also take non-domestic forms 
whereas IPV involves only a current or former intimate partner. It is also 
termed “partner violence”. A review found that in the general UK population 
between 1.8 and 4.5% were victims of IPV in the past year 2. This was higher 
in women than men (2.5-6.3% vs 0.9-2.7%). Earlier studies suggest that 
around a quarter of UK and Australian women are exposed to IPV at some 
time in their lives 3,4.
IPV is associated with serious physical and psychological harm to its direct 
victims. According to World Health Organization (WHO) approximately 42% 
of women who experience physical or sexual IPV, sustain injuries as a result 
5. Sexual IPV can result in unwanted pregnancy, miscarriage, sexually 
transmitted infections (STI) and other gynaecological problems 6–8.
Psychological effects of IPV may include fear, depression, low self-esteem, 
anxiety disorders, depression, headaches, obsessive-compulsive disorder, 
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post-traumatic stress disorder, low self-esteem, disassociation, sleep 
disorders, shame, guilt, self-mutilation, drug and alcohol abuse and eating 
disorders 9,10. IPV is also associated with harm to indirect victims, 
particularly other family members, such as children 11. 
In the light of this, screening and treatment for IPV has potential public 
health benefit. In the UK, the National Institute for Health and Clinical 
Excellence (NICE) has produced public health guidance [PH50] and a quality 
standard [QS116] on DVA 12,13. These recommend that frontline staff are 
trained to recognise DVA indicators and to ask relevant questions to support 
disclosure of IPV/ DVA and effective responses.  In addition, they 
recommend routine questioning about DVA in specific areas such as 
antenatal, postnatal, reproductive care, sexual health, alcohol or drug 
misuse, mental health, children and vulnerable adults’ services. Routine 
screening also occurs following certain injuries in Emergency Departments 
(ED), also called Accident and Emergency (A&E). Routine screening for DVA 
is not recommended outside of these so-called high-risk areas, in, for 
example, general practice and most outpatient clinics. NICE has no 
recommendations specifically for IPV. 
Policies in the other big-five areas examined in this review are as follows: 
Australia: Screening policies for domestic violence vary between 
jurisdictions.  In New South Wales and in Northern Territory, screening for 
such violence is routine. In Victoria, there is targeted screening for family 
violence. There are no universally accepted guidelines on screening.14,15 The 
Royal Australian College of General Practitioners says there is insufficient 
evidence for universal screening in clinical settings but says also there 
should be a “low threshold” [p.13] for asking about abuse.16
Canada: The Public Health Agency of Canada does not currently support 
routine screening for IPV.17 This recommendation is based on the review of 
evidence undertaken for the USPSTF.
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Ireland: The Health Service Executive (HSE) does not recommend universal 
screening for domestic violence.18 It recommends primary care staff be 
trained in a practice of recognise, respond and refer.
New Zealand: Guidelines from the Ministry of Health19 recommend routine 
enquiry concerning IPV among women of childbearing age, not just those in 
particular high-risk groups or areas.
United States: On the basis of a report by the US Preventive Services Task 
Force (USPSTF),20 guidelines recommend clinicians screen for IPV in all 
women of reproductive age and provide or refer women who screen positive 
to ongoing support services. A 2013 Government report sets out the state of 
practice at that time.21 Practice varies widely by State; the USA has a highly 
decentralized system of health care. However, screening rates are low, 
between 1.5% and 12% in primary care settings.22 
This current review examined areas outside those deemed high risk. These 
are areas that are generally not routinely covered by screening in the big-five 
areas. In relation to these areas, its aims were: 
1) To determine the accuracy of screening tools for intimate partner violence 
(IPV) in women and men, and in sub-groups based on ethnicity and sexual 
orientation; 
2) To determine the effectiveness of such screening and subsequent 
interventions in terms of, for example, reducing the rate of such violence. 
2 Methods
This was a rapid review of the literature as defined in the typology of Grant 
and Booth (2009). This method was chosen as a requirement of the funders. 
Here a caveat is required. The technology of rapid reviews is changing, 
particularly since the establishment in 2015 of the Cochrane Rapid Review 
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Methodology Group. This published guidance in 2020 24 This post-dated our 
review which, therefore, does not meet all its recommendations. This is a 
limitation of our study. Nonetheless, as a rapid review of the earlier type, it 
aims to examine a representative range of evidence on IPV in the clinical 
population that is not routinely screened (rather than all available evidence). 
We searched the Medline, PsycINFO, Embase and Cochrane Library 
databases. using the term “intimate partner violence” and synonyms, such 
as battered women and spouse abuse combined with terms related to 
incidence, prevalence and epidemiology. See Appendix 1 for full search 
strategy. Studies were included if they: 
1) concerned IPV affecting men or women aged 16 and above with no 
obvious signs or symptoms of abuse; (below this age, incidents are likely to 
be characterised differently, as, for example, child abuse); 
2) concerned i) the sensitivity, specificity, and positive and negative 
predictive values of screening tools designed to detect current or past IPV, 
including self-and clinician-administered or ii) the effectiveness of screening 
and subsequent interventions in terms of desired outcomes; 
3) were cross-sectional studies or cohort studies;
4) were published in English; 
5) were published up until January 16 2019 from: i) 1st January 2007 (for 
women) or ii) any date (for men and sub-groups of women by sexuality, 
pregnancy and ethnicity). The distinction between i) and ii) was set because 
the review was an update of earlier NSC reviews which included figures up 
to 2007 but which excluded men and only included women unspecified by 
sexuality, pregnancy or ethnicity; 
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6) concerned the use of screening in non-high-risk areas defined as those in 
which NICE already recommends proactively asking patients about IPV; this 
review was concerned with areas or groups where screening is not routinely 
undertaken
7) used data from the so-called big five geographic areas: UK and Ireland, 
USA, Canada, Australia and New Zealand. The big five countries were 
deemed to have sufficient cultural, health service and language similarities 
for the results to be relevant to the UK. 
There were 12 other relevant systematic reviews; these were hand-searched 
for additional articles 20,25–35. For the purposes of this article, an update 
search to 1st August 2020 was performed in Medline alone (see Results). 
Two reviewers undertook quality appraisal of all included papers. The 
following tools were used: CASP checklist for diagnostic test study 36; CASP 
checklist for RCT 37; and the appraisal tool for cross-sectional studies (AXIS) 
tool 38. The appraisals informed the analysis but no exclusion criteria were 
set on the basis of quality. This decision was made because of the small 
data set and the need therefore to draw on a broad data set.
Ethics
As this was a review of published evidence, no formal research ethics approval 
was required or sought. There was, however, an element of patient and public 
involvement (PPI): first, the review went for public consultation before 
publication and, second, there were 2 PPI representatives on the UK NSC (the 
funding body) who were involved in its review and development. 
3 RESULTS
After removal of duplicates, the original searches yielded 19186 results. 
These were divided into two groups: the first related to screening and its 
direct outcomes; the second, to interventions undertaken following 
screening in the groups covered by this review. 46 additional papers were 
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included by citation from other literature reviews. Following title and 
abstract review, 40 papers met the criteria for full text review in relation to 
screening and 22 papers in relation to intervention. An additional 66 articles 
were included from the update search, giving a total of 128. Of these, 106 
were not selected for extraction because they were in a high-risk setting 
(n=17), had no relevant data described (n=18) or were not relevant to our 
research questions (n=71).
This left 10 papers on screening and 13 on intervention. Of the 10 papers on 
screening, 6 related to accuracy 39–44 and 4 to effectiveness 45–48. There were 
13 papers on 12 interventions 49–58 59–61; note that El-Mohandes et al., 2008 
and Kiely et al 2010 report the same study. 
The PRISMA chart shows the reasons for exclusion of the other papers. We 
report the results in three sections, the first two on the accuracy and 
effectiveness of screening tools for IPV, the third on the effectiveness of 
interventions following screening. 
Figure 1 PRISMA CHART
3.1 Accuracy of screening tools for IPV 
A recent review 20 lists CTS-2, CAS and ISA the three gold standard 
validated reference tools; and these were used as the reference standard in 5 
of the 6 studies 41–43,62,63. These tools are, however, long and difficult to 
administer. In general, the aim of the studies used here was to validate a 
short tool, easy to administer in the clinical area, against the longer gold-
standard tools. The tools tested were the GASP, 39 PSQ, 62 HITS, 63, E-HITS 
42, 64 and HARK 41. The results are set out in Table 1.
INSERT TABLE 2 HERE
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Positive and negative predictive values (PPV and NPV) are included in the 
table where available. The key point is that PPV and NPV, unlike the more 
familiar specificity and sensitivity, take account of the prevalence of the 
condition. As such, they tell you the probability that someone following a 
positive or negative test result will truly have the condition. By contrast, 
specificity and sensitivity tell you the proportion of those who test positive or 
negative will have or not have the disease. NPV and PPV give a better 
indication of the clinical usefulness of the test 65.  
Sohal was the sole UK study included in this review 41. It involved the 
administration of questionnaires to women in GP waiting rooms. It found 
the four-item HARK questionnaire to have good sensitivity and specificity 
(against CAS as reference standard); the authors concluded that their study 
suggests HARK may be an effective tool. Dubowitz looked at the 3-item PSQ 
used with parents in a paediatric clinic 62. Sensitivity was low but specificity 
was high (against CTS-2 as reference standard). The authors note that 1 of 
the 3 items of the PSQ, the one relating to physical assault, was almost as 
effective as the 3 items together. They conclude that this item could be used 
as a reasonably effective one-question quick-scan tool. Iverson (using CAS 
as reference standard) established that a cut-off score of 6 on the HITS tool 
gave best overall scores, as shown in the table. The authors conclude that 
the results are promising for the use of HITS. A similar conclusion 
concerning a modified HITS tool is drawn by Portnoy in relation to a sample 
of US women veterans 42. Finally, Soglin et al look at a tool designed 
specifically for the South Asian population (as defined in US terms) and find 
it promising, albeit with a small sample. In addition, the cultural specificity 
of the US definition of South Asian populations would mean it would need 
separate testing in other contexts 64.
Only one study reviewed concerned a group other than women. This was a 
study conducted in Canada which examined screening in gay male 
relationships 39. The authors noted that no other research tested an abuse-
screening tool with gay males. They developed a tool GASP – Gay Abuse 
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Screening Protocol. This had two initial questions taken as the screening 
questions which would be followed up by the clinician if either were positive. 
The three last questions specifically ask whether the person has suffered 
physical, psychological or sexual abuse; these were taken as the standard 
against which the two initial questions were assessed. The authors were 
primarily concerned with physician and patient comfort with the tool; the 
comfort scores for both groups were high, although lower in abused rather 
than non-abused patients. They conclude that the tool merits further 
investigation.
3.2 Effectiveness of screening tools for IPV
Four papers from two studies were reviewed. One study was a large RCT, 
45,46,48 the second, a smaller study 66.
The large RCT looked at screening using the 3-item PVS 45,46,48. There were 
three study groups: group 1 received the PVS via Computer-Assisted Self-
Interview (CASI) and were provided with a local resource list and shown an 
information video if they screened positive; group 2 received no screening, 
but were provided with the local resource list; group 3 received no screening 
or resource list. At 1-year, the groups were compared for incidents of IPV, 
quality of life (mental and physical health), hospitalisation, Emergency 
Department (ED) visits and ambulatory visits (i.e. out-patient visits). At 3-
years, the groups were compared for hospitalization, ED visits and 
ambulatory visits. No significant differences were found across the three 
groups for any of the outcomes at 1-year or at 3-years.
The researchers also examined knowledge and attitudes regarding IPV at 1 
year in the same participants 45. The data are cut into various groups based 
on the intervention received plus the women’s own experience of IPV. The 
key finding is that no differences were found on the basis of either type of 
intervention; this is with one fairly minor exception: “women who were 
provided a list of IPV resources without screening were significantly less 
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likely to know that IPV is not the victim’s fault than those in the control or 
list plus screening conditions [i.e., groups]”.
The smaller study tested the accuracy of PVS administered face-to-face and 
by computer assisted self-interview (CASI). If either method resulted in a 
positive score for PVS the trial went on to examine the effect of three types of 
support. The first was face-to-face healthcare professional support and 
referral to relevant agencies – this was provided to those who had completed 
the PVS face-to-face. Those who completed the CASI either received a 
printout of local resources and encouragement to contact these or they 
received a short video clip talking about support and encouraging help 
seeking, plus the printout of resources. 126 women were randomised to the 
study (46 face-to-face). At one week, 96% recalled receiving the list: 4/36 
(11%) of those screened by healthcare professional had taken up services 
from the list versus 2/66 (3%) of the comparator group. They conclude that 
the tool merits further investigation.
3.3 Effectiveness of interventions following screening for IPV
Of the 13 papers on intervention, 7 related to non-pregnant women 
52,53,55,56,58–60 and 6 related to pregnant women 49–51,54,57,61; two of these 6 
papers reported on one study 54,57. Three studies were from Australia 50,55,60, 
the remainder from the USA. 
In line with the objectives of this paper, all the interventions followed 
screening; they did, however, vary in type. They included motivational 
interviewing 52, counselling sessions by phone or face-to-face 56,67 which 
could be provided by trained advocates 67 or clinical staff 53,68.  Table 2 gives 
a summary of the interventions.
Insert Table 2 here
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Effectiveness was measured against various outcomes, particularly IPV 
exposure, mental health, quality of life, and IPV knowledge and safety 
promoting behaviours. Taking these in turn, 5 studies looked at the impact 
of the intervention on IPV exposure in non-pregnant women 52,55,56,58,60 and 
6 in pregnant women 50,51,54,57,61,69. No study found statistically significant 
effects in non-pregnant women. By contrast, 3 of the 5 studies in pregnant 
women fo nd an effect 51,54,57,69, 1 study was insufficiently powered 50, 
whilst one failed to find a statistically significant effect 61.
4 Discussion
Accuracy of screening for IPV
Three tools are considered gold standard: CTS-2, CAS and ISA. Four brief 
and easy to administer tools were tested in the clinical areas that were the 
focus of this review. The tools were GASP, HITS, E-HITS and HARK. GASP 
was aimed at screening in gay male relationships and was the only one not 
concerned with women in heterosexual relationships. No tools were designed 
specifically for pregnant women. The tools had no adjustment for cultural or 
ethnic differences. The small number of studies and limited amount of data 
mean that it is at present not possible to recommend a particular tool for 
use in so-called non-high-risk areas. However, they each showed some 
promise. As such, given the prevalence and impact of domestic and intimate 
partner violence, there is good reason to continue to test the tools. In 
addition, the adjustment of the tools and development of new tools based on 
different ethnicities, sexuality and on pregnancy is indicated by our findings.
Effectiveness of screening for IPV
The search found only two studies reported in four papers on the 
effectiveness of screening tools as an intervention in itself that might, for 
example, increase knowledge or reduce violence. This was insufficient to 
draw clear conclusions on whether screening is effective in this regard. The 
small amount of evidence found suggested it is plausible that screening plus 
an intervention such as provision of educational materials is more effective 
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than provision of educational materials alone. We might hypothesize that 
this is because screening helps better to target the provision of such 
materials.
Effectiveness of interventions following screening for IPV
Twelve interventions reported in 13 papers were found in this review. The 
interventions were of various types and were tested against a wide range of 
outcomes. The key outcome is probably IPV exposure; an intervention for 
those who had been found by screening to be exposed to IPV and which 
reduced further exposure would be extremely desirable. The other outcomes 
measured might be taken as proxies for this main outcome, such as 
education, or as desirable counter-measures to the harm of IPV, such as 
improved mental health. 
In this regard, the small number of studies and, in some cases, their lack of 
statistical power, led to disappointing results. In terms of reducing IPV 
exposure, there is little there is little statistically significant difference 
between intervention and control groups, although where there are 
tendencies these favour the intervention groups. One set of researchers 
caution against using IPV exposure as an outcome as they say it is unlikely 
to change significantly in the period of a RCT 55. As such, the signs of 
improvement in both proxy and counter-measure outcomes might be 
deemed sufficient evidence to recommend their use. Again, the evidence is 
insufficient to recommend any particular interventions at a policy level, but 
is probably sufficient to recommend further research in the clinical areas 
that are the focus of this review.
Study limitations 
A rapid review design was used in accordance with the requirements of the 
funder and the associated short time frame available. This is less thorough 
than a systematic review. For example, there was no search for grey or 
unpublished literature. In addition, quality appraisal of the articles was 
performed but not used formally in a meta-analysis. Finally, as already 
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noted, the rapid review was performed under guidelines set out before the 
most recent update 24.  
Despite this, the review shows that there is at present insufficient evidence 
to support routine use of screening or interventions for IPV in non-high-risk 
clinical areas or at general population level. However, there are simple 
screening tools that are promising and which clinicians would be justified in 
using as part of a research protocol, in particular the screening tools HARK, 
PSQ and HURT. The same applies mutatis mutandis to some interventions, 
from brochure-based empowerment tools delivered during routine health 
visits to more intensive counselling or CBT. Given the prevalence and harm 
caused by IPV, such research is urgently required.  The shortfall in evidence 
is particularly marked in relation to sub-groups such as gay men, lesbians 
and ethnic minorities.
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Figure 1 PRISMA CHART
Records identified through database 















Full-text articles reviewed against 
eligibility criteria and included = 128
Screening = 40
Intervention = 22 
Additional = 66
Additional articles included from 
hand-searches of other reviews  
Screening = 46
Intervention = 0 
Articles selected for extraction and 
data synthesis = 23
Screening accuracy = 6
Screening effectiveness = 4 
Post-screen intervention = 13
Articles not selected for 
extraction = 105
High risk setting = 17
No relevant data described = 18 
Not relevant = 70
Additional articles included 
from update search Aug 2020 = 
66
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Table 1: Accuracy of IPV Screening Instruments
Author, Year, 
Setting




Prevalence Sensitivity % 
(95% CI – 
where given)
Specificity % 
(95% CI – 
where given)
PPV % (95% 
CI – where 
given)
NPV % (95% 










(95% CI – 
where given
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Table 2: Interventions following screening for IPV
Authors, year country, Population, setting Intervention Outcome Comments
General group
Coker et al 2012, USA 751 Women Attending 
Primary Care (447 
intervention, 304 control)
Intervention: In clinic 
advocacy provided by a 
clinic-based IPD advocate;
Control: Usual care; IPV+ 
women were given the 
business card of their health 
care provider with the 
coalition hotline number.
IPV exposure – measured by 
WEB plus follow-up and 17-
item Danger Assessment 
Score: no statistically 
significant difference over 6 
months
Mental Health: No 
differences regarding self-
perceived mental health over 
time but intervention group 
scored better for depressive 
symptoms and suicidal 
ideation over time [6 months] 
(p= 0.01).
Quality of life – not measured
Safety seeking behaviour: 
measured using help-seeking 
questions in USA National 
Violence Against Women 
Survey. Intervention women 
were more likely to use 
services provided by the 
advocate (p=0.03)
Less than 50% response rate; 
Not a fully cluster-
randomised controlled trial (3 
out of 8 clinics not 
randomised); selection bias; 
high refusal rate (54%); high 
attrition as only a small 
number completed follow up 
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Garcia et al 2019, USA 90 women from Personal 
Empowerment Programs 
(PEP) conducted at domestic 
violence agencies in Orange 
County, California.




IPV was assessed with the 
Revised Conflict Tactics 
Scale.
The Personal Progress Scale–
Revised was used to measure 
empowerment. 
The Perceived Stress Scale–
Short Form was used to 
assess perceived stress. 
The Center for 
Epidemiological Studies–
Depression Scale short form 
was used to assess depressive 
symptoms. 
The Derogatis Affects 
Balance Scale was used to 
assess mood and affect before 
and after the PEP class. 
Current and past experiences 
with relaxation techniques 
and exercise were assessed 
through a six-item 
questionnaire asking whether 
the participant had practiced 
relaxation or exercise (a) 
currently, (b) ever, and (c) 
how often. 
Non-randomised study with 
correlational statistics only. 
Many possibilities for bias or 
unclear direction of 
causation. Little longitudinal 
data therefore findings 
limited to before and after one 
session.
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Saliva was collected using 
Salivettes immediately before 
and after the 2-hr PEP class. 
Saliva.
Practicing relaxation 
techniques correlated with 
more empowerment. For 
women without sexual abuse 
experiences only, having 
completed more classes (>5 
classes) in the program was 
associated with greater 
empowerment, less stress, 
and fewer depressive 
symptoms. 
Gillum et al 2009, USA 41 women screened positive 
for IPV in past year (21 
intervention, 20 control)
Intervention: One on-site and 
6 telephone counselling 
sessions over a 3-month 
period by a community health 
worker – average duration 20 
minutes
Control: Received health 
information brochures, a list 
of community resources, and 
a monthly telephone call to 
confirm contact information.
IPV exposure – measured 
using Partner Violence 
Screen, Partner Abuse Scale 
and Danger Assessment 
Score2. No statistically 
significant difference 
between groups.
Mental health – depression 
and PTSD measured using 
Center for Epidemiologic 
Studies-Depression Scale. No 
statistically significant 
difference between groups.
Quality of life – not measured
Small sample; selection bias, 
women may not have 
reported abuse at true scale; 
response bias
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Safety promoting behaviour: 
measured using 15-item 
checklist. Intervention group 
significantly more likely to 
engage in safety-promoting 
behaviours p < 0.01 – on 
average, those who received 
the intervention engaged in 
3.47 more safety-promoting 
behaviours.
Hegarty et al 2013, Australia Multiple family practice 
clinics (roughly UK GPs); 
Women 16-50 who screened 
positive for fear of their 
partner in the past 12 months 
(137 intervention, 135 
control)
Intervention: Physician 
training to respond to women 
who screen positive for IPV 
and deliver a brief in-person 
IPV counselling intervention 
to screen positive women – 
average duration 30 minutes 
– frequency varied by patient 
need
Control: Usual Care
IPV exposure – measured 
using CAS – no significant 
differences
Mental health – measured 
using SF12 - no significant 
differences in anxiety; no 
significant differences in 
depression at 6 months – but 
at 12 months, fewer women 
in treatment arm had 
depressive symptoms 
[Adjusted Odds Ratio 0.4 
(95%CI 0.2 to 0.8); p= 0.006.
Quality of life – measured 
using WHO Quality of life – 
BREF No statistically 
significant differences 
Help seeking behaviour: 
safety planning and 
Fair to good quality RCT; 
lack of masking of providers 
and patients - low rate of 
attrition (6% for doctors and 
28% for patients); Slightly 
more women in comparison 
group were living with 
partner and had children 
younger than 18 years. 
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behaviour or mental-health 
SF-12 at 12 months. No 
statistically significant 
differences.
No adverse events recorded
Hegarty et al 2019, Australia 422 women aged 16-50 who 
had screen positive for any 
type of IPV. 
Online interactive healthy 
relationship tool and safety 
decision aid (I-DECIDE)





No effect from intervention in 
terms of depression and 
possible negative effects in 
terms of self-efficacy. No 
effects met pre-specified 
statistical levels.
RCT – good quality. 
Miller et al 2018, USA 25 family planning clinics (17 
clusters) 4009 women 16-29 
who agreed to a follow-up 
interview 
Clinician and staff training 
(medical assistants, health 
educators) to deliver in-
person universal screening/ 
education, and brief 
counselling (emphasising 
harm reduction strategies) for 
IPV/reproductive coercion; 
additional support, including 
referrals to victims’ services, 
provided to those who 
screened positive 
Control: usual care
Reproductive coercion – 
measured using ten-item tool: 
no significant differences at 
T2 (12-20 weeks) and T3 (12 
months) (times pooled) 
Adjusted Risk Ratio [ARR] 
(95% CI) 1.5 (0.95 to 2.35)
IPV – measured using 3-item 
tool – unclear which: no 
significant difference ARR 
1.07 (0.84 to 1.38)
Mental Health – Not 
measured
Limited generalisability; lost 
to follow-up rate high (21% 
at 12 months); those lost to 
follow-up had a higher 
prevalence of IPV at baseline; 
Analysis controlled for 
missing data by using 
imputations; Usual care was 
not well described  
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Quality of life – Not 
measured
Help seeking – Statistically 
significant difference in 
knowledge of IPV-related 
resources in intervention 
group 4.25 (3.29 to 5.5) but 
no difference in harm 
reduction behaviours.
Other – no significant 
differences in pregnancy 
(unintended or intended), or 
use of harm reduction 
behaviours.
Saftlas et al 2014, USA 2 family planning clinics; 
women screened positive for 
IPV by a current partner 
within the past year and had 
to be aged 18 years or older, 
English-speaking, and neither 
currently pregnant nor 
incarcerated.
155 intervention (98 
completed)/ 155 control (106 
completed)
In-person motivational 
interviewing by trained 
coordinator or onsite certified 
domestic abuse advocate 
focussing on individual goal 
setting to improve health and 
increase safety – total around 
90 minutes. (Content: 
physical health, emotional 
health, social support, quality 
of work or home life, or their 
relationship)
Control: Provision of written 




Self-efficacy – measured by 
modified version of Domestic 
Violence Coping and Self-
Efficacy Scale – no 
statistically significant 
difference
Depressive symptoms – 
measured using Centre for 
Epidemiologic Studies Short 
Depression Scale – no 
Recruitment was less than 
anticipated and made study 
lack statistical power; lack of 
masking; High overall 
attrition but no significant 
differential attrition (33% 
including 2 with missing 
data)























































– measured using tool 
adapted from research in the 
area – no statistically 
significant difference
Pregnant specific group
El-Mohandes et al 2008 / 
Kiely et al 2010, USA
African American women 
≥18 years, ≤28 weeks’ 
gestation and reporting any of 
4 risk factors;
Subgroup experiencing IPV 
screened positive for any IPV 




person CBT from trained 
social worker or psychologist 
a med at reducing 
behavioural risks 
(depression, IPV, smoking, 
and tobacco exposure); 
sessions targeted toward 
specific risks reported by 
women at that session.
Prenatal: 3.9 (mean); range 





Frequency determined by 
Mothers’ attendance at 
routinely
Scheduled perinatal care 
visits); 
IPV exposure – unclear what 
tool used – may have been 
disclosure at interview – 
during pregnancy and 
postpartum women in the 
intervention group were 
statistically less likely to have 
recurrent episodes of intimate 
partner violence (adjusted 
odds ratio 0.48; 95%CI 0.29-
0.80); the chance of being an 
IPV victim at any point in the 
study was significantly lower 
in the intervention group 
(23.3% v 37.8% p=0.006 – no 
confidence intervals); 
however postpartum data 
analysed alone does not reach 
statistical significance.
Pregnancy and birth 
outcomes – intervention 
group had fewer very preterm 
Risk of selection bias and 
recall bias; High refusal rate 
(31% of women approached 
declined to participate; 15% 
of those who agreed and met 
eligibility criteria, declined 
further participation; Higher 
attrition rate (26%); 
imputations were used to 
control for missing data.
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Control: Usual Care neonates (1.5% v 6.6%; 
p=0.03) and an increased 
mean gestational age 
(38.2±3.3 vs 36.9±5.9; 
p=0.16)
Mental health outcomes – not 
measured
Quality of life – not measured
Help seeking behaviour – 
measured by resolution of 
risks in the postpartum period 
– the intervention group were 
more successful at resolving 
all risks (47% v 35% 
p=0.007) and in resolving 
some risks (65% v 54% 
p=0.009).
Feder et al 2018, USA Intervention delivered 
through Nurse Family 
Partnership (NFP) – a home 
visiting program for 
promoting maternal and child 
health by community nurses 
to low income, 
primogenitors.
330 women of 1056 
approached took up NFP. 
Further dropout left a sample 
Intervention had three 
components:
nurse training and 
screening assessment of 
IPV, a secondary 
prevention component for 
those reporting IPV,
and a primary prevention 
component for all 
participants.
Levels of perpetration of 
physical, psychological and 
sexual IPV measured by 
CTS2. No main effect found 
on any of these outcomes in 
those screened and showing 
IPV. There was an 
(unexpected) positive effect 
for women who had not 
showed IPV on first screening 
in that those in intervention 
group showed lower levels of 
RCT. Low take up of NFP. 
Zelen randomization has 
statistical and ethical 
concerns.  Sample size small 
given low base rates of IPV in 
sample. 
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of 238 women who were 
randomised using Zelen 
randomisation.
physical and psychological 
IPV.
Sharps et al 2016, USA Women ≥14 years, ≤32 
weeks’ gestation, screened 
positive for
current IPV, low income 
enrolled




DOVE) Brochure-based IPV 
empowerment intervention 
embedded into a perinatal HV
programme; tailored to a 
woman’s expressed needs 
and level of danger; delivered 
during routine HVs – 
duration up to 2 years 
postpartum
Control: Standard home-
visiting protocol (4–6 
prenatal visits, 6–12 postnatal 
visits over 2 years)
IPV exposure – measured 
using CTS2 – there was a 
significant decrease in IPV at 
all points from baseline to 24 
months postpartum (both 
intervention and control 
group) p<0.001). There was 
also a significant treatment 
effect (F=6.45; p<0.01). 
Treatment group had larger 
mean decrease in IPV scores 
from baseline (mean 40.82 v 
35.87).
Pregnancy and birth 
outcomes – not measured
Mental health outcomes – 
measured using Edinburgh 
Postnatal Depression Scale – 
mean levels of maternal 
deprivation did not differ 
across groups at any time 
point in the study (all p>0.05)
Quality of life – not measured 
Help seeking behaviour – not 
measured
Risk of selection bias; high 
overall attrition rate (55% at 
24 months); varied 
randomisation procedures by 
site. At urban centres 
randomisation was by 
participants (computer 
generated number 
assignment), at rural health 
agencies cluster 
randomisation was used for 6 
sites; method of cluster 
randomisation- not clear 
Taft et al 2011, Australia 106 Primary Care clinics; 
Women aged 16 and over, 
Weekly HVs offering non-
professional befriending, 
IPV exposure – measured 
using CAS – findings 
Enrolled women screened 
positive for IPV or self-
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pregnant or had at least one 
child five years or younger, 




advocacy, parenting support 
and referrals – Duration 12 
months
Control: Usual Clinician Care
consistently favoured 
intervention group but did not 
reach statistical significance 
– the closest was reduced 
partner violence: odds of 
experiencing violence at 
follow-up adjusted for 
baseline abuse were 0.47 
(95%CI 0.21-1.05).
Pregnancy and birth 
outcomes – not measured
Mental health outcomes – 
measured using Edinburgh 
Postnatal Depression Scale – 
favoured intervention but did 
not reach statistical 
difference Adjusted 
Difference of OR -1.90, 
95%CI -4.12 to 0.32.
Quality of life – measured 
using SF-36 difference 
favouring intervention did 
not reach statistical 
significance.
Help seeking behaviour – not 
measured
In addition – there seemed to 
be no difference with regard 
to the Parenting Stress Index.
disclosure of IPV status; 
selection bias; intervention 
and control arm were not of 
same size; imputations were 
used to manage missing data; 
high attrition 
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Zlotnick et al 2018, USA Perinatal women, 18 years of 
age or older, English-
speaking, and reported 
experiencing IPV in the past 




A computerized based 
intervention (acronym 
SURE) delivered on a tablet 
computer. It included a parrot 
avatar with a female voice 
that addresses the participant 
by name, serves as a guide 
and narrator for the 
programme. Focused on 
personalised safety planning. 
Optional printouts of related 
materials; This was followed 
by a telephone/ in-person 10–
15-min booster session to 
review goals and motivators, 
barriers to increasing safety 
behaviours and achieving 
goals.
Control: watching brief 
segments of popular 
television shows and 
following up with questions 
for ratings of their preference.
IPV exposure –measured 
using CAS – total 
victimization scores for 
women in intervention group 
decreased by 14.8 points at 4-
month follow up and was 
unchanged in the non-
intervention group. The 
reduction was significant on a 
paired t-test p<0.001. Each 
subscale of CAS showed a 
reduction but only with 
statistical significance in the 
emotional subscale.
Pregnancy and birth 
outcomes – not measured
Mental health outcomes – not 
measured
Quality of life – not measured
Help seeking behaviour – not 
measured
In addition, the SURE 
intervention was scored 
acceptable and helpful by 
participants.
Small sample size; feasibility 
study; limited generalisability 
as single site study; selection 
bias; response bias; high 
refusal rate from those invited 
to participate (32%); attrition 
rate (8%);   
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